Navigation Links
Halozyme Reports First Quarter 2013 Financial Results
Date:5/8/2013

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"With the potential for 3 new product launches over the next 12 months and continued progress on the Hylenex® brand, I am pleased with the steps we are making towards our near term revenue drivers," said Gregory I. Frost , Ph.D., President and Chief Executive Officer, Halozyme. "Moreover, over the next 8 weeks, we will present a first-look at clinical data from our innovative pipeline products, PEGPH20 and HTI-501."

Highlights of Halozyme's first quarter activities and recent events include:

  • The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion to Baxter for the use of HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies.
  • Initiated a 124 patient Phase 2 clinical study evaluating PEGPH20, a proprietary, investigational drug, as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Patients in the study will receive gemcitabine and nab-paclitaxel either with or without PEGPH20. The primary endpoint will be to measure progression-free survival.
  • Initiated a 400 patient Phase 4 clinical study – The CONtinuous Subcutaneous Insulin infusion STudy ENrolling Type 1 Diabetes (CONSISTENT 1) – that will evaluate Hylenex use in conjunction with rapid analog insulin in people with Type 1 diabetes using insulin pumps. The primary endpoints include metabolic and safety outcomes.
  • Investigators at Yale
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. Halozyme Reports First Quarter 2012 Financial Results
    3. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
    4. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
    5. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
    6. Halozyme Reports Second Quarter 2012 Financial Results
    7. Halozyme to Host Third Quarter Financial Results Conference Call
    8. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    9. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
    10. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
    11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)...  Lockton Dunning Benefits, the Dallas ... addition of Vice President Kim Foerster ... Consulting team, Excelsior Solutions. Foerster ... the position.  Most recently, she worked as the ... Pharmacy, where she has held various managerial positions ...
    (Date:12/24/2014)... Tianyin Pharmaceutical Co., Inc. (NYSE MKT: ... biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... the Company achieved the Public Notice (Gong Shi) ... of TPI,s Qionglai Facility (QLF) from the China ... period is a significant procedure of GMP certification ...
    (Date:12/24/2014)... DUBLIN and RALEIGH, N.C. ... subsidiary of Endo International plc (NASDAQ: ENDP ... BDSI ) announced today that they have ... Buccal Film to the U.S. Food and Drug Administration ... the management of pain severe enough to require daily, ...
    Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
    ... May 2, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... Ltd. (NASDAQ: TEVA ) and Cephalon, Inc. (NASADQ: ... acquired by Teva.  In response to the news, Valeant has ... this announcement is positive news for Cephalon stockholders and we ...
    ... SAN JOSE, Calif., May 2, 2011 EMBEDDED SYSTEMS ... company, announces the availability of Prism FP ™ , ... lossless compression of floating point data types.   ... thousands or tens of thousands of computing nodes poses ...
    Cached Medicine Technology:Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2Samplify Systems Announces Availability of Prism FP Floating Point Compression 2
    (Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
    (Date:12/24/2014)... Connie Casad, MD, a well-known and ... with 30 years of practice experience in Dallas, Texas, ... benefits of dietary detoxification. The second study is scheduled ... results from test patients who just completed a 21-day ... interest in conducting the study, Dr. Casad said, "About ...
    (Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
    (Date:12/24/2014)... Dallas, TX (PRWEB) December 25, 2014 ... Analysis to 2023” focuses on the current treatment landscape, ... colorectal cancer market. Stivarga is a drug which is ... This drug is orally administered and is also prescribed ... The drug which is FDA approved is a multi-kinase ...
    (Date:12/24/2014)... 24, 2014 (HealthDay News) -- The holidays can be a ... off by certain foods and drinks. "This is the ... trigger attacks of migraine," Dr. David Dodick, chair of the ... foundation. "It,s important to think through food and beverage ... attack," added Dodick, a professor of neurology at the Mayo ...
    Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Expert Offers Tips for Preventing Holiday Migraines 2
    ... 15th, on Capitol Hill, the Center for Medicine in ... a question-and-answer session for media and Congressional Staff entitled: ... Experts Discuss Patient Safety." The event will be co-hosted ... Commerce Committee, Congresswoman Anna Eshoo (D-CA) and Congressman Mike ...
    ... have long been committed to expanding coverage to the millions ... know all too well what lack of coverage means for ... rooms every day. As a nation, we know we can ... with Chairman Baucus and the Obama Administration to move comprehensive ...
    ... ANGELES, July 8 Social Compassion in Legislation ... pet overpopulation through legislation, today reported that the total ... municipal shelters increased 14.6 percent statewide - from 378,445 ... released figures from the California Department of Public Health ...
    ... , WASHINGTON, July 8 Today, the American Hospital ... announced an agreement with the White House and Senate ... spending by $155 billion. Cost savings is an ... the national association representing physician owned hospitals. As always, ...
    ... says, , WEDNESDAY, July 8 (HealthDay News) -- Scientists ... monoclonal antibody drug might safely cure anthrax poisoning in ... they are not effective in killing the toxins produced ... those toxins once they enter the bloodstream. After an ...
    ... 8 Watson Pharmaceuticals, Inc. (NYSE: WPI ... today announced that its subsidiary, Watson Laboratories, Inc., has ... Administration to market its over-the-counter Nicotine Polacrilex Gum USP, ... fruit and cinnamon flavors. , , Nicotine Polacrilex ...
    Cached Medicine News:Health News:CMPI to Host Hill Briefing on Follow-On Biologic Drugs for Media and Congressional Staff with Reps. Eshoo and Rogers 2Health News:Statement About Agreement With White House and Senate Finance Committee on Health Reform 2Health News:California Department of Public Health Reports Large Increase in Pet Euthanasia 2Health News:California Department of Public Health Reports Large Increase in Pet Euthanasia 3Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 2Health News:Physician Hospitals of America Charges: Hospital Associations Bargain Away $155 Billion in Medicare Funding in Attempt to Destroy Physician Hospitals 3Health News:New Drug Fights Anthrax Toxin 2Health News:New Drug Fights Anthrax Toxin 3Health News:Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums 2
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: